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 Reporting a lethal drug interaction occu-
rred during evaluation of insulin resistance 
in mice polycystic ovary model 
 
Sir, 
Hormonal and metabolic imbalance can effect women's 
health and reproductive system from the view point of 
endocrinology (Borna et al., 2012; Boroujeni et al., 2016). 
Polycystic  ovary  syndrome is  an  example  of  such 
endocrinology  disorders.  Type  2  diabetes,  obesity, 
metabolic  syndrome,  hypertension  and  so  on  are 
considered as risk factors of polycystic ovary syndrome. 
Metformin is used for the treatment of polycystic ovary 
syndrome, because of insulin resistance in such patients 
(Keshavarz et al., 2017; Yari et al., 2017). The exact 
etiology of polycystic ovary syndrome is not clear, 
because metabolic disorders (e.g. insulin resistance) and 
hormonal  disorders  (e.g.  hyperandrogenism)  are 
simultaneously observed.  
Since insulin resistance in previous murine models of 
polycystic ovary syndrome has not been evaluated, we 
were trying to approve this research modeling through 
empirical administration of insulin glargine. The mice 
model of polycystic ovary syndrome through testos-
terone  enantate  has  been  previously  validated 
histologically and biochemically by some researchers 
(Ahmadi et al., 2017; Kalhori et al., 2014).  
For the current experimental study 22 female and 7 
male mice were used. The animals were grown and 
kept in animal laboratory of Razi Herbal Medicine 
Research  Center,  Lorestan  University  of  Medical 
Sciences considering ethical guidelines of working with 
laboratory  animals  (ethical  code:  IR.LUMS.REC. 
1396.351).  Their  thermos  contained  dextrose  5% in 
water (D5W) instead of distilled water which was free 
access for the mice in order to prevent unwanted hypo-
glycemia related death. The mice divided into 4 groups: 
Group 1: Polycystic ovary syndrome modeling group, 
administered with 2 mg/100 g testosterone enantate 
soluted in olive oil; Group 2: Female insulin suscepti-
bility control group, administered with 1 unit/18 g 
insulin glargine; Group 3: Male insulin susceptibility 
control group, administered with 1 unit/18 g insulin 
glargine; and Group 4: Female group for combined 
administration  of  testosterone  enantate  and  insulin 
glargine  in  order  to  induce  hyperinsulinemia  and 
insulin resistance (which finally showed a lethal drug 
interaction). All the administrations were daily for 2 
weeks.  Death  in  1st  48  hours  of  starting  insulin 
administration considered as insulin susceptibility. For 
Group 1, insulin administration were performed after 
this two week procedure. In order to analyze the data 
Fisher's exact test was used.  
In  the  polycystic  ovary  syndrome modeling  group 
(Group 1),  all  the  animals  survived after  2  weeks 
administration of testosterone enantate, and also survi-
ved after empirical administration of insulin. Three out 
of 7 animals in the female insulin susceptibility controls 
(Group 2), died in the 1st 48 hours. All the male insulin 
susceptibility controls (Group 3), survived after insulin 
administration. In the combined administration group 
(Group 4), all the mice died after 1st administration. 
Insulin resistance in the modeling group was higher in 
comparison to  the female controls,  but it  was not 
statistically significant (p=0.19). The results of Group 4 
showed a drug interaction of testosterone enantate and 
insulin glargine. This result was statistically significant 
in comparison to other groups (p<0.05) (Table I).  
The non-significant statistical result of Group 1 versus 
Group 2 showed that this method of empirical insulin 
administration could not show the insulin resistance of 
polycystic ovary syndrome model. This might be due to 
our low sample size or low power of analysis. Investi-
gation of serum insulin level was our financial limita-
tion. On the other hand, our significant results of Group 
4 versus the other groups showed that this dose of 
combined administration of testosterone enantate and 
insulin glargine could be at least the absolute lethal 
dose (LD100) of this combination. Based on Food and 
Drug Administration (FDA) suggested formula,  the 
ratio of mice mg/kg to human mg/kg is 37/3 (Ahmadi 
et al., 2015). Our dose for testosterone enantate and 
insulin glargine were 2 mg/100 g and 1 unit/18 g 
respectively (= 20 mg/kg and 55 unit/kg). The human 
equivalent would be 1.62 mg/kg and 4.46 unit/kg. 
Hence for a 62 kg individual who has administered an 
injection of testosterone enantate 100 mg, 276 units of 
insulin  glargine  will  be  a  killing  dose,  but  this 
nevertheless  shows  that  testosterone  enantate  can 
increase the hypoglycemic effect of insulin (Kapoor et 
al., 2006) and in such conditions insulin dose should be 
adjusted.  
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 The highlights of our study fall into some categories. 
The most important one is that this model of insulin 
resistance  evaluation  is  not  successful.  The  drug 
interaction of testosterone enantate and insulin glargine 
is  statistically  approved.  Testosterone  can  reduce 
insulin resistance and increase hypoglycemia. This give 
us clue that testosterone administration is not a suitable 
modeling for polycystic ovary syndrome in laboratory 
animals, because testosterone will not induce insulin 
resistance and these are mutually exclusive. It shows 
the unknown etiology of polycystic ovary syndrome.  
Funding and ethical approval: Razi Herbal Medicine Research 
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Table I 
Summary of the findings (above) and analysis (below)   
 Group 1  Group 2  Group 3  Group 4  
Survived Dead Survived Dead Survived Dead Survived Dead 
Number 7 0 4 3 7 0 0 8 
Inter-group comparison of significance 
p value Group 1  Group 2  Group 4  Group 3  
Group 1                 
Group 2 0.19              
Group 3 1  0.19          
Group 4 0.0002a  0.02a  0.0002b      
aSignificant and conclusive; bSignificant but not conclusive (because of male/female bias) 
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